Enterovirus A71 vaccine effectiveness in preventing enterovirus A71 infection among medically-attended hand, foot, and mouth disease cases, Beijing, China

References

• Podin Y, Gias EL, Ong F, Leong YW, Yee SF, Yusof MA, Perera D, Teo B, Wee TY, Yao SC, et al. Sentinel surveillance for human enterovirus 71 in Sarawak, Malaysia: lessons from the first 7 years. BMC Public Health. 2006;6:180. doi:10.1186/1471-2458-6-180.
   PubMed Web of Science ®Google Scholar
• Chan LG, Parashar UD, Lye MS, Ong FG, Zaki SR, Alexander JP, Ho KK, Han LL, Pallansch MA, Suleiman AB, et al. Deaths of children during an outbreak of hand, foot, and mouth disease in Sarawak, Malaysia: clinical and pathological characteristics of the disease. For the outbreak study group. Clin Infect Dis. 2000;31:678–83. doi:10.1086/314032.
   PubMed Web of Science ®Google Scholar
• Fujimoto T, Chikahira M, Yoshida S, Ebira H, Hasegawa A, Totsuka A, Nishio O. Outbreak of central nervous system disease associated with hand, foot, and mouth disease in Japan during the summer of 2000: detection and molecular epidemiology of enterovirus 71. Microbiol Immunol. 2002;46:621–27.
   PubMed Web of Science ®Google Scholar
• Chan KP, Goh KT, Chong CY, Teo ES, Lau G, Ling AE. Epidemic hand, foot and mouth disease caused by human enterovirus 71, Singapore. Emerg Infect Dis. 2003;9:78–85. doi:10.3201/eid0901.020112.
   PubMed Web of Science ®Google Scholar
• Van Tu P, Thao NTT, Perera D, Truong KH, Tien NTK, Thuong TC, How OM, Cardosa MJ, McMinn PC. Epidemiologic and virologic investigation of hand, foot, and mouth disease, southern Vietnam, 2005. Emerg Infect Dis. 2007;13:1733–41. doi:10.3201/eid1311.070632.
   PubMed Web of Science ®Google Scholar
• National Health Commission of the People’s Republic of China. National surveillance of epidemic situation of notifiable communicable diseases in 2017 in China. Reviewed Jan 18 [accessed 2018 July 6]. http://www.nhfpc.gov.cn/jkj/s3578/201801/178264d9c8ab4d439a34284a4c84fee7.shtml.
   Google Scholar
• Xing W, Liao Q, Viboud C, Zhang J, Sun J, Wu JT, Chang Z, Liu F, Fang VJ, Zheng Y, et al. Hand, foot, and mouth disease in China, 2008–12: an epidemiological study. Lancet Infect Dis. 2014;14:308–18. doi:10.1016/S1473-3099(13)70342-6.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Jit M, Wu JT, Yang J, Leung K, Liao Q, Yu H. Economic costs and health-related quality of life for hand, foot and mouth disease (HFMD) patients in China. PLoS One. 2017;12:e0184266. doi:10.1371/journal.pone.0184266.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Yang J. Estimation of social economic burden caused by fatal hand, foot and mouth disease cases in China, 2013–2015. Dis Surveillance. 2017;32:516–20.
   Google Scholar
• Li R, Liu L, Mo Z, Wang X, Xia J, Liang Z, Zhang Y, Li Y, Mao Q, Wang J, et al. An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med. 2014;370:829–37. doi:10.1056/NEJMoa1303224.
   PubMed Web of Science ®Google Scholar
• Zhu F, Xu W, Xia J, Liang Z, Liu Y, Zhang X, Tan X, Wang L, Mao Q, Wu J, et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med. 2014;370:818–28. doi:10.1056/NEJMoa1304923.
   PubMed Web of Science ®Google Scholar
• Zhu FC, Meng FY, Li JX, Li XL, Mao QY, Tao H, Zhang YT, Yao X, Chu K, Chen QH, et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2013;381:2024–32. doi:10.1016/S0140-6736(13)61049-1.
   PubMed Web of Science ®Google Scholar
• Boom JA, Tate JE, Sahni LC, Rench MA, Hull JJ, Gentsch JR, Patel MM, Baker CJ, Parashar UD. Effectiveness of pentavalent rotavirus vaccine in a large urban population in the United States. Pediatrics. 2010;125:e199–207. doi:10.1542/peds.2009-1021.
   PubMed Web of Science ®Google Scholar
• De Serres G, Skowronski DM, Wu XW, Ambrose CS. The test-negative design: validity, accuracy and precision of vaccine efficacy estimates compared to the gold standard of randomised placebo-controlled clinical trials. Euro Surveill. 2013;18:20585. doi:10.2807/1560-7917.ES2013.18.37.20585.
   PubMedGoogle Scholar
• Foppa IM, Haber M, Ferdinands JM, Shay DK. The case test-negative design for studies of the effectiveness of influenza vaccine. Vaccine. 2013;31:3104–09. doi:10.1016/j.vaccine.2013.04.026.
   PubMed Web of Science ®Google Scholar
• Li J, Lin C, Qu M, Li X, Gao Z, Zhang X, Liu Y, Huang Y, Wang X, Jia L, et al. Excretion of enterovirus 71 in persons infected with hand, foot and mouth disease. Virol J. 2013;10:31. doi:10.1186/1743-422X-10-31.
   PubMed Web of Science ®Google Scholar
• Gu W, Zeng G, Hu YM, Hu YS, Zhang Y, Hu YL, Wang Y, Li JX, Zhu FC. A comparative analysis of immunogenicity and safety of an enterovirus 71 vaccine between children aged 3–5 years and infants aged 6–35 months. Expert Rev Vaccines. 2018;17:257–62. doi:10.1080/14760584.2018.1430572.
   PubMed Web of Science ®Google Scholar
• Sullivan SG, Tchetgen EJ, Cowling BJ. Theoretical basis of the test-negative study design for assessment of influenza vaccine effectiveness. Am J Epidemiol. 2016;184:345–53. doi:10.1093/aje/kww064.
   PubMed Web of Science ®Google Scholar
• Fukushima W, Hirota Y. Basic principles of test-negative design in evaluating influenza vaccine effectiveness. Vaccine. 2017;35:4796–800. doi:10.1016/j.vaccine.2017.07.003.
   PubMed Web of Science ®Google Scholar
• Feng S, Cowling BJ, Kelly H, Sullivan SG. Estimating influenza vaccine effectiveness with the test-negative design using alternative control groups: a systematic review and meta-analysis. Am J Epidemiol. 2018;187:389–97. doi:10.1093/aje/kwx251.
   PubMed Web of Science ®Google Scholar
• Jackson ML, Phillips CH, Benoit J, Kiniry E, Madziwa L, Nelson JC, Jackson LA. The impact of selection bias on vaccine effectiveness estimates from test-negative studies. Vaccine. 2018;36:751–57. doi:10.1016/j.vaccine.2017.12.022.
   PubMed Web of Science ®Google Scholar
• Deiss RG, Arnold JC, Chen WJ, Echols S, Fairchok MP, Schofield C, Danaher PJ, McDonough E, Ridore M, Mor D, et al. Vaccine-associated reduction in symptom severity among patients with influenza A/H3N2 disease. Vaccine. 2015;33:7160–67. doi:10.1016/j.vaccine.2015.11.004.
   PubMed Web of Science ®Google Scholar
• VanWormer JJ, Sundaram ME, Meece JK, Belongia EA. A cross-sectional analysis of symptom severity in adults with influenza and other acute respiratory illness in the outpatient setting. BMC Infect Dis. 2014;14:231. doi:10.1186/1471-2334-14-231.
   PubMed Web of Science ®Google Scholar
• Foppa IM, Ferdinands JM, Chaves SS, Haber MJ, Reynolds SB, Flannery B, Fry AM. The case test-negative design for studies of the effectiveness of influenza vaccine in inpatient settings. Int J Epidemiol. 2016;45:2052–59. doi:10.1093/ije/dyw022.
   PubMed Web of Science ®Google Scholar
• Yang W, Li Z, Lan Y, Wang J, Ma J, Jin L, Sun Q, Lv W, Lai S, Liao Y, et al. A nationwide web-based automated system for outbreak early detection and rapid response in China. Western Pac Surveill Response J. 2011;2:10–15.
   PubMedGoogle Scholar
• Wang X, Wu X, Jia L, Li X, Li J, Li S, Qian H, Wang Q. Estimating the number of hand, foot and mouth disease amongst children aged under-five in Beijing during 2012, based on a telephone survey of healthcare seeking behavior. BMC Infect Dis. 2014;14:437. doi:10.1186/1471-2334-14-437.
   PubMed Web of Science ®Google Scholar
• Qin Y, Zhang Y, Wu P, Feng S, Zheng J, Yang P, Pan Y, Wang Q, Feng L, Pang X, et al. Influenza vaccine effectiveness in preventing hospitalization among Beijing residents in China, 2013–15. Vaccine. 2016;34:2329–33. doi:10.1016/j.vaccine.2016.03.068.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wu P, Feng L, Yang P, Pan Y, Feng S, Qin Y, Zheng J, Puig-Barbera J, Muscatello D, et al. Influenza vaccine effectiveness against influenza-associated hospitalization in 2015/16 season, Beijing, China. Vaccine. 2017;35:3129–34. doi:10.1016/j.vaccine.2017.03.084.
   PubMed Web of Science ®Google Scholar